1. Home
  2. AIMD vs GDTC Comparison

AIMD vs GDTC Comparison

Compare AIMD & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIMD

Ainos Inc.

HOLD

Current Price

$1.66

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$1.02

Market Cap

12.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIMD
GDTC
Founded
1984
2018
Country
United States
Singapore
Employees
44
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
12.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AIMD
GDTC
Price
$1.66
$1.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.9K
7.0K
Earning Date
05-11-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.73
52 Week High
$4.50
$3.68

Technical Indicators

Market Signals
Indicator
AIMD
GDTC
Relative Strength Index (RSI) 57.86 45.92
Support Level $1.33 $0.97
Resistance Level $1.72 $1.06
Average True Range (ATR) 0.10 0.04
MACD 0.03 -0.00
Stochastic Oscillator 63.92 61.93

Price Performance

Historical Comparison
AIMD
GDTC

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: